Fractyl Health, Inc. (GUTS)
NASDAQ:GUTS
Want to see GUTS full AI Analyst Report?
GUTS Stock Chart & Stats
$0.57
-$0.12(-5.94%)
At close: 4:00 PM EST
$0.57
-$0.12(-5.94%)
Day’s Range― - ―
52-Week Range$0.38 - $3.03
Previous Close$1.96
Volume269.01K
Average Volume (3M)2.22M
Market Cap
$125.29M
Enterprise Value$55.85M
Total Cash (Recent Filing)$63.17M
Total Debt (Recent Filing)$60.82M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Aug 19, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.74
Shares Outstanding158,648,960
10 Day Avg. Volume1,704,873
30 Day Avg. Volume2,221,060
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)17.64
Price to Sales (P/S)0.00
P/FCF Ratio-1.84
Enterprise Value/Market Cap0.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.61
Forecast
1Y Price Target
$5.00Price Target Upside777.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.45
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pivotal Trial ExecutionA fully randomized pivotal (>300 patients) with >90% retention and a reassuring blinded safety profile materially de-risks clinical execution and regulatory review. This durable evidence base improves odds of approval, hospital adoption, and payer engagement versus early uncontrolled data.
Rejuva Clinical AdvancementAuthorization to start RJVA-001 Phase 1/2 makes Fractyl a dual clinical-stage company, diversifying risk beyond a single device program. A one-time, pancreas-targeted GLP-1 gene therapy could provide durable T2D benefit and long-term commercial optionality if clinical signals persist.
Cost Discipline And Operating ImprovementSustained reductions in R&D and operating spend with a meaningful adjusted EBITDA improvement demonstrate better capital stewardship. Improved operating efficiency extends runway toward key 2026 milestones and lowers dilution risk if the company sustains this discipline.
Bears Say
Pre‑Revenue And Large LossesBeing pre-revenue with persistent, large net losses (~$108M TTM) means the business depends on future clinical success to generate revenues. This structural profile elevates execution and financing risk and compresses flexibility until the company demonstrates commercial traction.
Constrained Cash RunwayA runway into early 2027 with the ATM closed and no planned raise before pivotal readouts creates a structural financing cliff. Any trial delays or additional spending needs could force dilutive financing or constrain commercialization planning ahead of regulatory milestones.
Elevated Leverage Versus EquityMeaningful leverage relative to a small equity base limits financial flexibility for a pre-revenue biotech. High debt servicing or covenant risk can complicate strategic choices and raise refinancing needs, especially if clinical timelines slip or additional capital is required.
Fractyl Health, Inc. News
GUTS FAQ
What was Fractyl Health, Inc.’s price range in the past 12 months?
Fractyl Health, Inc. lowest stock price was $0.38 and its highest was $3.03 in the past 12 months.
What is Fractyl Health, Inc.’s market cap?
Fractyl Health, Inc.’s market cap is $125.29M.
When is Fractyl Health, Inc.’s upcoming earnings report date?
Fractyl Health, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 77 days.
How were Fractyl Health, Inc.’s earnings last quarter?
Fractyl Health, Inc. released its earnings results on May 12, 2026. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of -$0.16 by $0.22.
Is Fractyl Health, Inc. overvalued?
According to Wall Street analysts Fractyl Health, Inc.’s price is currently Undervalued.
Does Fractyl Health, Inc. pay dividends?
Fractyl Health, Inc. does not currently pay dividends.
What is Fractyl Health, Inc.’s EPS estimate?
Fractyl Health, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Fractyl Health, Inc. have?
Fractyl Health, Inc. has 158,648,960 shares outstanding.
What happened to Fractyl Health, Inc.’s price movement after its last earnings report?
Fractyl Health, Inc. reported an EPS of $0.06 in its last earnings report, beating expectations of -$0.16. Following the earnings report the stock price went up 29.155%.
Which hedge fund is a major shareholder of Fractyl Health, Inc.?
Currently, no hedge funds are holding shares in GUTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fractyl Health, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.00 (777.19% Upside)
$5.00 (777.19% Upside)
Blogger Sentiment
Bullish
GUTS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.47%
12-Months-Change
Fundamentals
Return on Equity
-4573.89%
Trailing 12-Months
Asset Growth
19.68%
Trailing 12-Months
Company Description
Fractyl Health, Inc.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.
GUTS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasizes strong clinical execution, external validation, regulatory and reimbursement progress, and a clear catalyst timeline — all supportive of the company's strategic thesis. Financially, the company has reduced operating spend and improved adjusted EBITDA, but remains cash-limited with a runway into early 2027 and continues to report negative adjusted profitability. Several regulatory and operational uncertainties remain (RAPID implementation, full de novo approval, U.S. regulatory engagement for Rejuva) and the near-term plan is contingent on multiple upcoming clinical readouts. Overall, clinical and regulatory momentum and cost discipline are material positives, but the constrained cash runway and remaining execution/regulatory risks temper the outlook.View all GUTS earnings summariesGUTS Stock 12 Month Forecast
Average Price Target
$5.00
▲(777.19% Upside)
Technical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protara Therapeutics
―
―
Innate Pharma
―
Ownership Overview
6.53% Insiders
4.29% Mutual Funds
36.26% Other Institutional Investors
49.32% Public Companies and Individual Investors
Options Prices
Currently, No data available
---